(5) Tannok IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512.SOURCE Regeneron Pharmaceuticals, Inc.
Analysts estimate total revenue will fall 6.9% to $3.53 billion in the quarter due to the loss of patent exclusivity on some drugs and divestitures of major business lines.
Gyrations hit market, as traders drop oil, buy safety.
The Tarrytown, N.Y.-based biopharmaceutical firm had first-quarter revenue of $1.32 billion.